The global biotechnology industry is experiencing its most productive period of scientific and commercial innovation since the founding of the sector. GLP-1 receptor agonists for obesity and diabetes — led by Novo Nordisk's Ozempic and Wegovy — have created the fastest-growing drug class in pharmaceutical history, with Novo Nordisk surpassing $43 billion in 2025 revenue. mRNA technology platforms pioneered for COVID-19 vaccines are being repurposed for oncology, rare disease, and infectious disease. RNA interference therapeutics pioneered by Alnylam are establishing a new therapeutic modality with applications across metabolic, neurological, and cardiovascular disease.
The ten companies covered in this report collectively represent the full spectrum of modern biotechnology — from Novo Nordisk's metabolic disease dominance and Amgen's biosimilar scale to Vertex's cystic fibrosis monopoly, Regeneron's antibody discovery platform, and Alnylam's RNAi pipeline. Takeda's rare disease portfolio — built through the $62 billion acquisition of Shire — and CSL's plasma-derived therapy leadership represent the diversified biotechnology model at scale.
High-Growth Opportunities Assessed
• GLP-1 Receptor Agonists and Obesity
• mRNA Therapeutics Beyond COVID
• RNA Interference and Gene Silencing
• Cell and Gene Therapy
• Biosimilars and Biobetters
• Rare Disease and Orphan Drugs
• Oncology Biologics
• Plasma-Derived Therapies
• Neurological Disease Biologics
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Table of Contents
1. Executive Summary
2. Market Overview
3. High-Growth Opportunity Analysis
3.1 GLP-1 Receptor Agonists and Obesity
3.2 mRNA Therapeutics Beyond COVID
3.3 RNA Interference and Gene Silencing
3.4 Cell and Gene Therapy
3.5 Biosimilars and Biobetters
3.6 Rare Disease and Orphan Drugs
3.7 Oncology Biologics
3.8 Plasma-Derived Therapies
3.9 Neurological Disease Biologics
4. Competitive Landscape Overview
5. Regional Market Analysis
6. Company Profiles
7. Strategic Conclusions and Recommendations
8. Appendix
List of Tables
Table 1. Global Biotechnology Market — Segment and Regional Overview 2025
Table 2. GLP-1 Market — Revenue and Competitive Dynamics 2025
Table 3. Biosimilars — Market Size and Pipeline 2025
Table 4. Cell and Gene Therapy — Commercial Landscape 2025
Table 5. Rare Disease — Market Dynamics 2025
Table 6. World's Leading Companies Revenue Comparison 2023-2025
Table 7. World's Leading Companies R&D Investment 2023-2025
Table 8. World's Leading Companies M&A Activity 2023-2025
Table 9. World's Leading Companies Pipeline Assessment 2025
Table 10. World's Leading Companies Strategic Priorities 2025-2030
Companies Profiled
Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Pfizer
Roche
Viking Therapeutics
Structure Therapeutics
